Therapeutic Areas

Osiris is driven to deliver effective medical therapies that require fewer treatments and help improve surgical outcomes, while reducing the overall cost of care.

Therapeutic Areas Osiris
Today, Osiris is focused on addressing the unmet needs of wound care, orthopaedics, and sports medicine with a current product line that includes Grafix®, a placental derived membrane acting as a cover for acute and chronic wounds; Cartiform®, a viable osteochondral mesh for cartilage repair; and BIO4®, a viable bone matrix for bone repair and regeneration.
With more than 20 years of experience, Osiris is a global leader in the research and development of cellular regenerative medicine. We are driven by our belief that regenerative medicine provides treatment options that are not only better for patients, but also better for physicians and the healthcare system as a whole.

Wound Care

Today, chronic wounds affect some 6.5 million patients in the United States. These ailments can require lengthy treatments at significant costs to the healthcare system. As of 2009, an excess of $25 billion was spent annually in the United States on treatment of chronic wounds, while the annual cost of wound care products alone was projected to reach $15.3 billion by 2010.1

In the United States alone, roughly 30 million individuals suffer from diabetes, with nearly 1 million of those individuals affected by chronic wounds. While early detection and treatment of these chronic wounds helps reduce the potential for further complications such as infection, hospitalization, and amputation, an improvement to today’s standard of care could lead to dramatic improvements in health care costs and patient quality of life.

This is why Osiris Therapeutics is committed to developing regenerative medicine that provides better solutions to address the unmet needs of hard-to-treat wounds, including diabetic foot and venous leg ulcers. This is due in large part to our proprietary BioSmart™ cryopreservation process, which retains the native characteristics and inherent functionality of tissue. The results are safe, easy-to-use products that have been shown to be beneficial in supporting natural wound repair and decreasing the time it takes to close chronic wounds.

1. Sen CK, Gordillo GM, Roy S, et al. Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy. Wound Repair Regen. 2009 Nov–Dec; 17(6): 763–771. doi: 10.1111/j.1524-475X.2009.00543.x.

Sports Medicine

Sports medicine injuries result in more than 97 million physician visits a year in the United States, including over 18 million patients reporting musculoskeletal symptoms in the knee. For example, acute meniscal tears affect 61 out of every 100,000 people each year, and an estimated 36% of all athletes have articular cartilage damage in the knee. Osiris Therapeutics is developing products to address these needs, with the goal of returning patients to their active lifestyles.

Osiris Therapeutics’ regenerative approach to sports medicine focuses on augmenting the body’s natural healing process to repair damaged musculoskeletal tissues, including articular cartilage, meniscus, tendons, and ligaments. Osiris’ proprietary BioSmart™ process retains the native characteristics and inherent functionality of allograft tissues, including the structural matrix, growth factors, and viable cells. The results are cryopreserved products that have been shown to support the body’s natural healing process for improved, long-lasting musculoskeletal repair.


The use of biologics in orthopaedics is growing. In the U.S. alone, its use is estimated to exceed $2.2B, with bone graft substitutes representing approximately $1.7B of the market. This growth is reflective of the increasing number of surgeries the country has seen. For example, more than 600,000 spinal fusion procedures are performed annually, and that number is expected to continue its upward trajectory. Osiris Therapeutics is addressing the needs of this market by focusing on a regenerative approach to orthopaedics, developing therapies that augment the body’s natural healing process to repair bone and surrounding tissue.

Osiris’ proprietary BioSmart™ process retains the native characteristics and inherent functionality of allograft tissues, including the structural matrix, potent growth factors, and endogenous viable cells. The results are cryopreserved products that support bone repair without the challenges associated with autografts.